| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.048 | 0.4 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |